header logo image


Page 25«..1020..24252627..3040..»

Archive for the ‘Genetics’ Category

Ten Years of Unraveling the Genomics of Parkinson’s Disease – Technology Networks

Monday, January 20th, 2020

The International Parkinson Disease Genomics Consortium (IPDGC) has now been in existence for ten years. In an open accessarticlepublished in theJournal of Parkinson's Diseasethe consortium reviews the progress made over the past decade in the genomics of Parkinson's disease (PD) and related disorders including Lewy body diseases, progressive supranuclear palsy, and multiple system atrophy and looks ahead at its future direction and research priorities.

Since PD was first defined, it has been suspected that there was a genetic component. In June 2009, a small group of investigators met to discuss a potential research alliance focused on the genetics of PD. The outcome was the creation of the IPDGC, a group focused on collaborative genetics research, enabled by trust, sharing, and as little paperwork as possible. This article summarizes the efforts of the IPDGC to date and places these in the context of a decade of progress in PD genomics. It also discusses the future direction of IPDGC and its stated research priorities for the next decade.

The IPDGC was born out of a realization that no single investigator could deliver on the promise of modern human genetics in isolation, explained lead author Andrew Singleton, PhD, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. We realized that to truly leverage the incredible gains in genetic technologies in the PD space, at scale, would require a highly collaborative approach. This notion brought a small group of PD geneticists together with the common goal of building an effective, transparent, and functional collaboration.

Since its inception, the IPDGC has grown considerably, now including more than 100 scientists from around the world with meetings at least once a year. The focus has also expanded to include clinical and functional investigation of PD at scale. Most recently, the IPDGC initiated major research efforts in East Asia and Africa and has prioritized collaborations with ongoing major efforts in India and South America.

The coordinated analysis of genome-wide association (GWA) data was perhaps the first success for IPDGC and has continued to be a mainstay of our work, noted Dr. Singleton. This work has centered on available genome-wide SNP genotyping of IPDGC members case and control cohorts from the USA, Canada, England, Wales, The Netherlands, France, Germany, Italy, Spain, Austria, Finland, Norway, Estonia, and Australia. These studies have involved collaboration within IPDGC and with groups from industry, including Genentech and 23andMe. The source diversity and size of these sample series have grown considerably, from the first efforts that centered on around 1,500 cases and a similar number of controls, to the most recent effort that included dense genotyping in more than 50,000 cases and proxy-cases, and around 1.4 million controls. As in other disorders, as sample size has grown, so has power and the number of loci detected. Currently, there are about 90 known risk variants for PD.

Collaboration among IPDGC members has furthered knowledge, including:

Future challenges the consortium has identified include expanding the known genetic architecture; genetics in diverse ancestries; advanced cohort building; and creating PD resources for the research community.

The importance of the dissection of genetic risk in non-European ancestry populations has led the consortium to invest more in establishing research in underrepresented groups. With the support of the Michael J. Fox Foundation for Parkinsons Research, the IPDGC has initiated largescale efforts in South East Asia and China and across Africa. It is also working closely with collections centered in India, LUX-GIANT, and LARGE-PD.

The field of PD genetics is one that has changed dramatically over the last ten years, commented Dr. Singleton. There has been an exponential growth in our appreciation of the genetic architecture of the disease and a greater understanding of how to proceed with genetic prosecution of PD.

Our future path promises to expand this work and leverage its clinical, mechanistic, and biological potential. Thus, while we believe the work of the IPDGC has had a significant and lasting impact on our field over the last ten years, we are even more excited by the course we have charted for the next decade.

Reference:The International Parkinson Disease Genomics Consortium (IPDGC). (2020).Ten Years of the International Parkinson Disease Genomics Consortium: Progress and Next Steps. The Journal of Parkinson's Disease.DOI: 10.3233/JPD-191854.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See original here:
Ten Years of Unraveling the Genomics of Parkinson's Disease - Technology Networks

Read More...

Cobb-Vantress appoints genetics executive – The Poultry Site

Monday, January 20th, 2020

Today, Cobb-Vantress appointed Dr Mark Cooper as managing director of genetics to oversee the companys global genetic program. Effective immediately, Dr Cooper will continue work to achieve genetic gains and competitive advantage through alignment of Cobbs breeding program with its product strategy, developing a portfolio of products to meet growing global market needs. He will report to Dr Aldo Rossi, vice president of research and development (R&D).

In his new role, Dr Cooper will lead a global, multifunctional team, including Dr Rachel Hawken, senior director of genetics; Dr Manouchehr Katanbaf, senior geneticist; and Dr Sriram Krishna, senior geneticist. Prior to this appointment, Dr Cooper previously worked as director of product testing. Since joining Cobb, he has also served as pedigree geneticist responsible for male line development, European director of genetics, director of genetics for all of Cobbs breeding programs, and director of product management.

Cobb has been dedicated to genetic research and the responsible use of technology for over 100 years, said Dr Rossi. Dr Cooper has made a big impact in his nearly 20 years with Cobb, and were looking forward to the continued advancements we expect him to accomplish in this new position.

In his time at Cobb, Dr Coopers research has focused on technology development and implementation in the breeding program, welfare parameters and meat quality. He has also spent time with global business leaders and customers to understand and update the R&D team on the product portfolio needed for the future. Most recently, he led Cobbs product testing team, helping to evaluate the companys product performance and development.

Im honored to take on the position of managing director of genetics, said Dr Cooper. Im fortunate because Cobb invests a significant percentage revenue into research and development, allowing us to continue leading the way in genetic progress.

Dr Cooper earned a bachelors degree in poultry science from Texas A&M University, a masters degree in poultry genetics from the University of Georgia, and a PhD in poultry genetics from the University of Arkansas.

See more here:
Cobb-Vantress appoints genetics executive - The Poultry Site

Read More...

Study Yields Insight Into Genetic Architecture of Anxiety – Psych Congress Network

Monday, January 20th, 2020

A genome-wide association study has identified several human genome regions related to anxiety risk. Researchers published their findings online in The American Journal of Psychiatry.

The findings are an important step forward in understanding anxiety disorders and the contribution of genes, said lead author Daniel F. Levey, PhD, of Yale University in New Haven, Connecticut, and the Veterans Affairs Connecticut Healthcare Center.

Dr. Levey and colleagues tapped data from the VA Million Veteran Program, a biobank that includes genetic, environmental, and medical information, to compare the genomes of almost 200,000 people.

The study identified 5 locations on the human genome associated with anxiety in Americans of European descent and 1 location in African Americans. Gene variants at the locations, researchers explained, could increase the risk for anxiety.h

Scans Show Shared Brain Abnormalities With Mood, Anxiety Disorders

The strongest locations were near genes involved with global regulation of gene expression (SATB1) and the estrogen receptor alpha (ESR1), according to the study. Another location (near MAD1L1) was previously linked with bipolar disorder and schizophrenia risk.

The study provides the first significant genome-wide findings regarding anxiety in people of African ancestry, Dr. Levey noted.

Minorities are underrepresented in genetic studies, and the diversity of the Million Veteran Program was essential for this part of the project, he said. The genetic variant we identified occurs only in individuals of African ancestry and would have been completely missed in less diverse cohorts.

Some 18% of participants in the Million Veteran Program are African American.

Jolynn Tumolo

References

Levey DF, Gelernter J, Polimanti R, et al. Reproducible genetic risk loci for anxiety: results from 200,000 participants in the Million Veteran Program. The American Journal of Psychiatry. 2020 January 7;[Epub ahead of print].

Million Veteran Program study sheds light on genetic basis of anxiety [press release]. Baltimore, Maryland: Veterans Affairs (VA) Research Communications; January 7, 2020.

Read more here:
Study Yields Insight Into Genetic Architecture of Anxiety - Psych Congress Network

Read More...

Florida Genetic Information Bill Advances in House – Government Technology

Monday, January 20th, 2020

(TNS) Incoming House Speaker Chris Sprowls had little trouble Thursday convincing members of a House health-care panel to approve legislation that would prohibit life-insurance, long-term care insurance and disability-insurance companies from using customers genetic information in changing, denying or canceling policies.

Florida would become the first state to have such a law if Sprowls proposal is ultimately passed by the Legislature and signed by Gov. Ron DeSantis.

Members of the House Health & Human Services Committee passed Sprowls bill (HB 1189) without any debate, and committee Chairman Ray Rodrigues, R-Estero, praised Sprowls for introducing the bill.

I think our privacy is important. And I think its equally important to be a visionary, to look forward and I 'm happy that Florida is going to be the state that leads the way on this issue, Rodrigues said.

Insurance industry lobbyists, who opposed the measure, sat quietly, agreeing to waive their speaking time.

Curt Leonard, regional vice president for state relations for the American Council of Life Insurers, said his association had expressed concerns on the issue for the past two years.

Weve expressed our concerns with Speaker Sprowls and other interested parties on this issue going back to 2018. So theres no point in repeating the same things over and over again, in the interest of the committee's time, Leonard said. That being said, we do share the speaker-designates (Sprowls) concerns about privacy. I think it's a concern for everybody.

The bill will have to clear the Commerce Committee before it would be ready to go to the full House. Sprowls, R-Palm Harbor, is slated to become speaker after the November elections.

In addition to preventing insurers from using the information in making policy decisions, Sprowls bill also would block the companies from requiring or soliciting genetic information from applicants.

Sprowls said insurance companies have for years been able to sell policies without having access to the genetic data.

Insurance carriers have been successful without access to genetic information. They have been able to provide affordable coverage to consumers without genetic information. Insurance is about spreading risk, not guaranteeing the outcomes or rewards to the (carriers). And affordable life, disability, and health insurance should not be available simply to the genetic elite, Sprowls said.

While Sprowls influence looms large in the House, he must convince the Florida Senate to go along. For that, Sprowls said he will look to Sen. Kelli Stargel, R-Lakeland, to spearhead the issue.

Senate President Bill Galvano, though, told The News Service of Florida that he supports a potential compromise on the issue.

Leonard said a compromise would authorize consumers to use their private information any way they want to. And that might include them wanting to share their genetic science or genetic testing information, he said. So we dont like the idea that consumers will be handcuffed in how they use that information.

2020 The Orlando Sentinel (Orlando, Fla.) Distributed by Tribune Content Agency, LLC.

Link:
Florida Genetic Information Bill Advances in House - Government Technology

Read More...

Functional validity, role, and implications of heavy alcohol consumption genetic loci – Science Advances

Monday, January 20th, 2020

Abstract

High alcohol consumption is a risk factor for morbidity and mortality, yet few genetic loci have been robustly associated with alcohol intake. Here, we use U.K. Biobank (n = 125,249) and GERA (n = 47,967) datasets to determine genetic factors associated with extreme population-level alcohol consumption and examine the functional validity of outcomes using model organisms and in silico techniques. We identified six loci attaining genome-wide significant association with alcohol consumption after meta-analysis and meeting our criteria for replication: ADH1B (lead SNP: rs1229984), KLB (rs13130794), BTF3P13 (rs144198753), GCKR (rs1260326), SLC39A8 (rs13107325), and DRD2 (rs11214609). A conserved role in phenotypic responses to alcohol was observed for all genetic targets available for investigation (ADH1B, GCKR, SLC39A8, and KLB) in Caenorhabditis elegans. Evidence of causal links to lung cancer, and shared genetic architecture with gout and hypertension was also found. These findings offer insight into genes, pathways, and relationships for disease risk associated with high alcohol consumption.

Alcohol consumption is associated with over 60 diseases, with the risk of these comorbidities generally increasing with greater exposure (1). Excessive consumption of alcohol is considered a result of complex interactions between genetic and nongenetic risk factors. Nongenetic factors associated with levels of alcohol intake include gender (2), age at first alcohol use (3), duration of poverty and involuntary unemployment (4), and other lifestyle risk factors (5).

Meta-analysis from twin and adoption studies has shown that half of the variance for alcohol use disorder (AUD) is explained by genetic factors (6). The discovery of well-replicated risk loci, however, has been limited to the alcohol metabolizing genes alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Missense variants, rs1229984 (G-->A; p.Arg48His) in ADH1B and rs671 (G-->A; p.Glu504Lys) in ALDH2, are protective against higher alcohol consumption and alcohol misuse phenotypes (7). For example, in a meta-analysis of ~3800 European ancestry individuals, the ADH1B rs1229984 variant was strongly associated with reduced risk of alcohol dependence and lower number of maximum drinks in 24 hours (8). The ADH1B and other ADH and ALDH variants that are associated with alcohol consumption occur at low frequency among European ancestry populations but are more common in East Asian ancestry populations, where the standardized population prevalence of alcohol misuse is lower (9).

Larger samples and genome-wide screens have been used to identify previously unidentified loci beyond the ADH-ADLH cluster. Alcohol consumption phenotypes are of specific interest to the field as they are often more applicable to the wider population than the AUD criteria. Through genome-wide association studies (GWAS), single-nucleotide polymorphisms (SNPs) mapping to/near KLB, AUTS2, SERPINC1, ANKRD36, GCKR, PXDN, CADM2, HGFAC, SLC39A8, and TNFRSF11A have been associated with alcohol consumption in European ancestry populations at genome-wide significance (P < 5 108) (1015). However, apart from association signals at KLB and GCKR, strong evidence of replication has been limited.

In this study, our aim was to determine factors associated with heavy alcohol consumption in white British individuals from the U.K. Biobank (UKB) (www.ukbiobank.ac.uk/), alongside exploring the functional relevance of genome-wide significant variants using model organisms and data mining techniques.

The application of the phenotype definition resulted in the identification of 21,967 cases and 103,282 controls that had complete data for all covariates. The covariates included in the final logistic regression model and carried forward to the GWAS analysis were (table S1) age at recruitment, sex, smoking status (anytime versus never), property ownership (own versus rent), body mass index (BMI), Townsend deprivation index at recruitment, adopted as a child, and long-standing illness, disability, or infirmity (yes or no).

We tested for SNP-level association with our high alcohol consumption phenotype in UKB. A total of 11,141,077 SNPs survived central quality control (QC) by UKB and post-GWAS filtering for imputation quality and minor allele frequency. The GWAS data test statistics showed modest deviation from the null (GC = 1.09; Fig. 1, inset), although linkage disequilibrium (LD) score regression intercept = 1.02 suggests most of the inflation is consistent with polygenic architecture. We then carried forward lead SNPs at P < 5 106 from UKB to Genetic Epidemiology Research in Adult Health and Aging (GERA) for replication. We report validated associations that meet genome-wide significance in the meta-analysis of UKB and GERA, which also demonstrate nominal association with the same direction of effect in GERA (Table 1). A summary of all SNPs reaching P < 5 108 in UKB can be found in table S2. We identified six loci attaining genome-wide significant association with alcohol consumption after meta-analysis and meeting our criteria for replication: ADH1B (rs1229984; P_meta = 2.3 1066); KLB (rs13130794; P_meta = 5.7 1016); BTF3P13 (rs144198753; P_meta = 4.1 1029); GCKR (rs1260326; P_meta = 1.5 1013); SLC39A8 (rs13107325; P_meta = 6.7 109); and DRD2 (rs11214609; P_meta = 4.3 109) (Table 1).

Inset: QQ plot of expected versus observed GWAS results from UKB, demonstrating modest deviation from the null, GC = 1.09.

OR, odds ratio; CI, confidence interval.

Multiple distinct signals of association observed at alcohol consumption loci. Conditional analyses revealed an additional signal (P < 1 105) (Table 2) at the SLC39A8 locus (NFKB1). Given ADH1B and BTF3P13 are located <1 Mb apart on q23 of chromosome 4, we conducted a wider conditional analysis across a 1.5-Mb region, which included both SNPs. The analysis identified eight independent SNPs mapping to/near ADH1A, ADH1B, ADH4, ADH5, TSPAN5, and EIF4E. The signal mapping to BTF3P13 did not meet locus-wide significance in conditional analysis, suggesting a false positive for this variant.

Joint models refer to the estimated joint effects of all selected SNPs in a region (i.e., all independent SNPs are fitted together).

Previously reported loci. The signals described in this section meet our validated association criteria and have been reported for various alcohol phenotypes by other groups. The lead SNP at ADH1B, rs1229984 [risk allele frequency (RAF), 0.980; P = 3.3 1036; fig. S1A], is the missense variant (G-->A; p.His48Arg) that has been widely replicated. The lead SNP rs13130794 (RAF, 0.632; P = 4.0 109; fig. S1B) is located in the KLB locus and has been reported to be associated with alcohol intake in the UKB (11) and a separate European cohort of >98,000 individuals (10). The lead variant in chromosome 2, rs1260326 (RAF, 0.612; P = 2.6 108; fig. S1C), is in GCKR, a glucokinase regulatory gene. This specific SNP has been reported as genome-wide significant for alcohol consumption (i.e., drinks/week) in large-scale European ancestry (11, 13) and transethnic populations (15). The lead SNP rs13107325 (RAF, 0.928; P = 1.6 108; fig. S1D) is in the zinc transporter gene, SLC39A8, which has been linked in Europeans to AUD Identification Test (AUDIT) (14) and AUDIT-C outcomes, and to AUD diagnosis (15). Last, rs11214609 (RAF, 0.395; P = 4.3 109; fig. S1E) was the SNP in the DRD2 locus. DRD2 often has been cited in addiction phenotypes and has been identified for AUD, but not alcohol consumption (15).

Nonreplicated signals reported elsewhere. We also observed genome-wide significant evidence of association in UKB at FTO and CRHR1, but these signals could not be validated in GERA. There is, however, evidence for association with alcohol-related phenotypes at these loci from other studies. The lead SNP rs55872725 (RAF, 0.599; P = 2.6 108) is in the FTO gene. This locus has recently been reported to be associated with AUDIT-C and AUD diagnosis in European ancestry individuals (15). Different index variants were reported between studies, rs62033408 for AUDIT-C and AUD diagnosis outcomes, but the SNPs are in strong LD with each other (r2 = 0.92). The FTO locus has been strongly associated with BMI, obesity, and, subsequently, type 2 diabetes as a clinical end point. Our lead SNP in this locus is in complete LD (r2 = 1.0) with rs1558902 in Europeans, which is the lead SNP for BMI in the largest published GWAS to date (16). The CRHR1 locus, with rs1635291 (RAF, 0.754; P = 4.5 1010) as the lead SNP, has been identified through gene-based analysis in a previous alcohol consumption GWAS where never drinkers were excluded. However, no other groups have reported this locus directly through GWAS. Given the previous associations for these loci with covariates included in our analysis but not in the GERA dataset, we explored the potential for collider bias at rs55872725 when not adjusting for BMI, and rs1635291 when not adjusting for smoking; the results were consistent at 6.5 106 and 2.8 108, respectively. We also found our lead SNP in the CRHR1 locus to be in strong LD (r2 = 0.87) with a tag SNP rs1800547 for a common inversion polymorphism in 17q21.31 (17).

Of the six validated variants from the UKB and GERA cohorts, three were identified as expression quantitative trait loci (eQTLs) through the Genotype-Tissue Expression (GTEx) database (table S3). rs11214609 showed evidence of being an eQTL in various tissues for nearby genes, ANNK1 and TTC12. rs13130794 was associated with the expression of RFC1 in the cerebellar hemisphere and skeletal muscle and UDGH in blood. rs1260326 was a broader eQTL with evidence across eight loci and various tissues including skeletal muscle, thyroid, and adrenal glands. Table S4 describes the LD between the top eQTL SNP for any eQTL signal and the GWAS SNP. None of the SNP pairs demonstrated evidence of colocalization based on a threshold of LD r2 > 0.8.

The validated SNPs were submitted to Gene ATLAS to explore phenome-wide association study (PheWAS) outcomes in disease phenotypes via International Statistical Classification of Diseases, 10th Revision (ICD-10) codes. Evidence suggests that these SNPs contribute to a range of diseases including alcohol dependence, hypertension, skeletal disorders, gout, alcoholic liver disease, ischemic heart diseases, metabolic disorder, obesity, and diabetes mellitus (table S5). The ADH1B variant is associated with lipid metabolism disorder, giving further link between alcohol intake and liver fat accumulation.

A set of 37 loci, which reached 5 106 with heavy drinker status phenotype in UKB, were submitted to the Reactome Knowledgebase for pathway analysis (table S6). Six pathways across three distinct processes were found to be significant. The most prominent outcome related to signaling of phosphatidylinositol 3-kinase (PI3K) and PI3K/AKT pathways, particularly in reference to cancer. Dysfunction of the PI3K/AKT pathway is widely implicated in many cancers and is a key regulator of cell survival through downstream targets (18). The genes implicated in these pathways were KLB and ESR1 (fig. S2). The other two pathways were neurexins and neuroligins, driven by LRRTM4 and NRXN3, and TFAP2 (AP-2) family regulation of transcription of growth factors and their receptors, driven by ESR1.

Through genetic correlation analysis of the entire genome, we identified 21 significant correlations that survived multiple testing correction. These outcomes are summarized in Fig. 2. The traits with the strongest correlations included smoking variables [e.g., ever versus never smoked (rg = 0.48, PFDR = 2.60 1013) and age of smoking initiation (rg = 0.41, PFDR = 0.006)], several lung cancer outcomes [e.g., squamous cell lung cancer (rg = 0.37, PFDR = 0.006) and lung cancer (rg = 0.36, PFDR = 1.20 104)], and mothers age at death (rg = 0.41, PFDR = 1.60 104). Several education measures and mental health conditions were also found to have significant correlations.

Mendelian randomization (MR) was used to examine the causal relationship between our heavy drinker case-control phenotype and 111 selected traits and clinical outcomes. The number of SNPs used for instrumental variables for each outcome test varied between two and six. Twelve outcomes including four insulin-related and two lung cancer outcomes demonstrated nominal significance using the inverse varianceweighted (IVW) method, although only evidence of a protective effect for ischemic stroke survived multiple testing correction (table S7). The MR-Egger regression intercept demonstrated no evidence of horizontal pleiotropy for the 12 outcomes (P 0.11). Single SNP analysis revealed that rs1229984 was not included in the instrumental variable for ischemic heart disease (SNP or appropriate proxy not available in the outcome dataset). Given rs1229984 demonstrates a consistent and large effect size across genetic studies of alcohol-related phenotypes, it is questionable whether the outcome can be considered as truly representative for this disease.

To further explore the potential causal effect of heavy alcohol consumption on lung cancer outcomes and allow for potential pleiotropy that might be driven by smoking, we repeated our GWAS analysis stratified for smoking status (ever versus never) and performed MR to assess potential collider bias. The SNPs used as the instrumental variable in the original analysis were retained, and lung adenocarcinoma and lung cancer were the only outcomes investigated. Evidence of consistent outcomes was observed in both stratified groups using IVW, although lung cancer in never smokers was the only outcome that did not reach the statistical significance threshold (P = 0.085).

To verify whether validated genetic targets (i.e., ADH1B, GCKR, SLC39A8, and KLB) had a conserved role in phenotypic responses to alcohol, we investigated the acute effects of ethanol on the nematode worm, Caenorhabditis elegans. In comparison to wild-type animals, those with a loss-of-function mutation in the worm ortholog for ADH (sodh-1 in C .elegans) had a statistically enhanced ethanol response (Fig. 3) as has been previously described in detail (19). The effect of intoxicating ethanol on coordinated locomotion was next quantified for loss-of-function mutations in C. elegans glucokinase (GK; hxk-1) and solute carrier family 39 member 8 (SLC39A8; zipt-15) (Fig. 3). Without an ortholog for GCKR in C. elegans, we instead analyzed its downstream effector protein glucokinase itself. Loss-of-function mutations in these genes significantly reduced the effect of ethanol for GK and SLC39A8 (Fig. 3), underlining a conserved role for these genes in whole-animal responses to alcohol. We also quantified single mutations in the C. elegans orthologs for the -Klotho protein (KLB; klo-1 and klo-2) and found that individual mutations did not alter the ethanol phenotype (fig. S3A). A compound mutation of both klo-1 and klo-2 (20), however, did have a significantly enhanced ethanol effect (Fig. 3).

C. elegans with loss-of-function mutations in worm orthologs to ADH (sodh-1), glucokinase (hxk-1), solute carrier family 39 member 8 (zipt-15), and -Klotho protein (klo-2;klo-1) were exposed to ethanol, and the resultant effect on locomotion rate was determined. Results are presented normalized to locomotion of untreated worms [basal locomotion rate: 99.03 1.47 (Bristol N2 controls), 103.13 3.66 (sodh-1), 87.37 1.91 (hxk-1), 31.43 2.97 (zipt-15), and 99.90 21.7 (klo-2;klo-1)]. *P < 0.05.

To validate the effects seen in individual mutant strains, we performed RNA interference (RNAi) experiments to knock down expression of the contraindicated genes. In comparison to control, RNAi knockdown of GK (hxk-1) and SLC39A8 (zipt-15) resulted in the same phenotypic effects as did the mutations (Fig. 4). In our RNAi experiments, knockdown of ADH (sodh-1) did not result in a significant decrease. Similar to the KLB mutations, individual knockdown of C. elegans KLB (klo-1 or klo-2) did not statistically enhance the ethanol phenotype and neither did knocking down both klo-1 and klo-2 simultaneously (Fig. 4). The lack of effect in the double knockdown is perhaps expected given that RNAi efficiency can be reduced with multiple targets (21). To validate the alcohol effect of KLB in C. elegans in an alternative method, we performed RNAi on individual KLB genes in the mutant strain of the other ortholog (i.e., klo-1 RNAi in the klo-2 background; klo-2 RNAi in the klo-1 background). In both cases, there were exceptionally enhanced effects of ethanol similar to that seen with the compound mutant strain (fig. S3B).

RNAi knockdown of worm orthologs to glucokinase (hxk-1) and solute carrier family 39 member 8 (zipt-15) phenocopies the loss-of-function mutations. Results are presented as locomotion of worms treated with ethanol normalized to untreated worms [basal locomotion rate: 87.63 21.6 (empty vector control), 94.17 2.91 (sodh-1), 77.60 2.34 (hxk-1), 60.0 2.34 (zipt-15), 90.97 3.56 (klo-1), 99.13 2.78 (klo-2), and 110.0 3.40 (klo-2;klo-1)]. *P < 0.05; n.s., not significant.

We report here a large alcohol consumption GWAS, including 125,249 white British participants, with subsequent replication and meta-analysis in an additional 47,967 individuals. Moreover, and as promoted by Salvatore and colleagues in this field (22), we conducted a post-GWAS study to investigate the biological implications of our findings. This includes providing evidence of a conserved role in phenotypic responses to alcohol for all targets available for investigation (ADH1B, GCKR, SLC39A8, and KLB) in C. elegans.

The primary strengths of this study are the (i) large sample size; (ii) replication and subsequent meta-analysis; (iii) post-GWAS analysis, including functional assessment using C. elegans; and (iv) use of a mixed-model approach in GWAS to account for relatedness. There are, however, several limitations that require discussion. First, the alcohol data and, therefore, the case-control phenotypes are based on self-reported alcohol intake. It is well documented that individuals underreport their alcohol consumption for a number of reasons. This presents risk of cases being mislabeled as controls, alongside the granularity of the data being reduced by the categorical approach. There are also differences in the measurement scale between discovery and replication cohorts. This difference was handled by applying a z score approach to meta-analysis. Second, we restricted analysis to those of white British ancestry to limit population structure variability on outcomes. This restricts generalizability outside of European populations. Third, we recognize limitations to our MR approach: (i) MR is considered most powerful when instrumental variables are from a continuous trait. This is of greater concern, however, when a disease-specific phenotype is used for instrument selection because of the likely contribution of various factors in disease pathology; and (ii) an inherent assumption of MR is that variants show no pleiotropy or direct effects on the outcome. This requires knowledge of the underlying biology under investigation, although this is rarely complete. Last, we were unable to undertake functional assessment of all genome-wide significant loci due to there being either no specific C. elegans orthologs, or too many nonspecific orthologs, or fatal consequences of gene knockdown.

The largest and most robust effects were observed in ADH1B, including replicated findings from the work in C. elegans for ADH (19), providing confidence for the selected phenotype. The biological validity of polymorphisms in ADH loci is well documented and discussed in detail in other GWAS publications (12).

KLB has been previously associated with alcohol phenotypes in European populations (10, 12). A biological basis for KLB has been proposed in mice, where those lacking -Klotho had increased alcohol consumption (10). This behavior was refractory to recombinant fibroblast growth factor 21 (FGF21), a hormone involved in sugar intake regulation and for which -Klotho is an obligate coreceptor. Hence, down-regulation of KLB may lead to sustained intake of alcohol and/or high-sugar food. Moreover, loss of both KLB isoforms in C. elegans caused an enhancement in the ethanol effects. Further evidence for energy processing pathways being implicated in alcohol consumption is demonstrated by the genome-wide significant outcomes for GCKR and SLC39A8, with these findings being consistent with recent publications (11, 13, 14). The data from our functional work in hexokinase and ZRT/IRT-like protein transporter supports the role of glucose metabolism pathways in the susceptibility to heavy alcohol consumption by demonstrating attenuation of the depressive effects of high-dose alcohol when hxk-1 and zipt-15 are independently knocked down. Although we failed to demonstrate replication between the UKB and GERA cohorts, potentially due to variation in phenotype, evidence from other GWAS showed consistent effects for FTO (23). The suggestive association with this pleiotropic locus adds further plausibility of common pathways implicated in the consumption of food and alcohol. The purported shared pathogenic architecture may result in dysregulation of brain reward pathways leading to excess consumption (24). Controlling for BMI within our GWAS suggests that the associations for alcohol consumption are independent of BMI, adding weight to the hypothesis of a potentially shared, rather than mediated, pathways.

DRD2 encodes the dopamine receptor 2 subtype and is linked to several neurobiological processes, including functional activation of reward circuits (25). Data from in vivo and in vitro experiments show DRD2 to be a susceptibility gene for alcohol dependence (26), and altering DRD2 expression leads to differential responses to substances and stimuli (27), conferring increased risk for addiction. Moreover, evidence suggests increased risk of relapse in alcohol and cocaine dependence, and heightened heroin, nicotine, and glucose craving when polymorphisms of DRD2 are present or there is low D2 receptor availability (28). The association of DRD2 with alcohol was confirmed in GWAS findings for AUD but not alcohol consumption, with authors proposing that the central nervous system is a fundamental element in the progression to clinical diagnosis (15). Our findings are somewhat contradictory given that participant categorization is based on U.K. alcohol units consumed per week, although the quantities for cases are often associated with high risk of AUD.

Together, the loci outside of the ADH/ALDH cluster suggest several common pathways associated with different types of compulsive behavior and addiction phenotypes. Considerable evidence from animal models and from humans supports convergence of these common etiologies in the brains limbic system regardless of the prior distinct mechanism of action and ultimate observable phenotype (29, 30). This suggests that addiction might be better considered as a pathobiological risk with different endotypes, rather than each specific phenotype (e.g., alcohol dependence, drug addiction, and gambling addiction) being independently characterized. From a therapeutics perspective, these outcomes provide additional and supportive evidence toward a number of targets that might be amendable to pharmacological intervention. Further investigation is required to determine which sites have the greatest potential. Data from the Open Targets resource (www.opentargets.org/) suggest that 49 drugs have reached phase IV investigation for DRD2 across a range of indications, including mental health disorders and cocaine dependence; no drugs are in development for ADH1B, KLB, GCKR, or SLC39A8. FGF21 has been explored due to links with KLB, but no drugs are in the market yet.

Using the GWAS outcomes from UKB enabled us to examine the relations between key variants/loci and traits and disease phenotypes. Genetic correlation analysis and MR consistently demonstrated an association with lung cancer. Determining alcohols contribution to lung cancer often has been limited by the strong positive correlation between alcohol intake and smoking. However, the outcomes from the MR provide potential evidence of a causal relationship in our overall sample and when stratified by smoking status. Alcohol is a known carcinogen and is implicated in cancers of the liver, colon, rectum, head and neck, and breast, for example (31), while evidence for lung is variable (32, 33). Lung cancer is a complex and multifactorial disease involving genetic and a range of measurable and nonmeasurable environmental and lifestyle factors. Hence, heavy alcohol consumption is one potentially modifiable risk factor to reduce disease incidence. An alternative hypothesis is through a joint risk locus in KLB that independently drives alcohol consumption and cancer risk. In addition to the above, -Klotho inhibits PI3K and, subsequently, AKT, an important pathway in normal cell function. The dysfunction of the PI3K/AKT pathway, identified in our pathway analysis, has been cited in cancerous cells and as a risk factor in cancer onset (18, 34). Down-regulation of KLB has been reported across several cancers (35, 36). However, some variations in findings exist (37), and no evidence is available in lung cancer. Basic cell line study would provide initial data on -Klotho expression in lung tumor cells.

Links to other diseases were also found. Drinking heavily was suggested as a protective factor for ischemic stroke. This is not consistent with traditional epidemiological findings or other MR findings using rs1229984 as the instrumental variable (38). However, the lack of rs1229984 in our instrumental variable for this analysis means the outcome should be interpreted with caution. The nominal evidence in several insulin measures suggests a wider biological association with glucose regulation, linking back to the potential importance of energy metabolism pathways in alcohol consumption. ADH1B and GCKR were associated with gout, and ADH1B alone with hypertension. The lead SNP at GCKR, rs1260326, has been shown to be a risk variant for gout in a separate GWAS (39), and rs1229984 in ADH1B has been identified for systolic blood pressure using a functional enrichment approach. Increasing alcohol consumption is a known risk factor for both gout and hypertension (40). Last, there was evidence for several skeletal complications with identified alcohol consumption variants. Alcohol intake represents a dose-dependent risk factor for fragility fractures due to the direct effects of alcohol on bone cell metabolism. Chronic alcohol consumption has been associated with a twofold increased risk of hip fracture in prospective cohort studies involving more than 16,000 subjects (41).

Our findings offer insight into genes, pathways, and causal relationships for disease risk associated with heavy alcohol consumption. The inclusion of model organism work to investigate the conserved role of loci alongside GWAS outcomes is novel in the alcohol field and adds validity for relevant outcomes. In addition, the correlation between the C. elegans phenotypic data with genome-wide association in humans reinforces a link between the acute physiological effect of alcohol and predisposition to excessive alcohol consumption. Specific findings suggesting joint reward/addiction pathways, the role of energy metabolism, casual links to lung cancer, and shared genetic architecture with gout and hypertension are of particular interest. Further investigation is required, however, to realize the potential of these outcomes and result in meaningful populationor clinical-level impact.

UKB is a large population cohort of ~502,000 individuals from the United Kingdom aged 40 to 69 years at the time of recruitment. Baseline assessment was undertaken at one of 22 centers across the United Kingdom between 2006 and 2010. Each participant completed a comprehensive demographic, lifestyle, and health questionnaire, underwent clinical phenotyping, provided biological samples (i.e., blood, urine, and saliva), and agreed to have his or her health record accessed for baseline and follow-up outcomes (42). Ethical approval for UKB was gained from the Research Ethics Service (REC reference: 16/NW/0274), and written informed consent was obtained from all participants. The current analyses were conducted under approved UKB data application number 15110.

Phenotype definition. Questions from the UKB baseline assessment were used to develop two study groups: heavy drinkers (cases) and drinkers not reaching criteria for cases (controls). All participants who indicated they consumed alcohol were asked to quantify their intake per week or per month using standard drink sizes [e.g., In an average WEEK, how many glasses of RED wine would you drink? (there are six glasses in an average bottle)]; pictures accompanied these questions to provide visual representation of each measure. We then applied a standardized number of U.K. alcohol units to each drink to enable an estimated number of units per week to be calculated (see the Supplementary Materials for more detail). Sex-specific heavy drinking was then defined as >35 U/week for women and >50 U/week for men. Any cases with values >4 SDs above the gender-specific means were removed. Controls were individuals who were not current abstainers from alcohol (i.e., 1 U/week) but did not reach the sex-specific criteria for heavy drinking and were drinking at similar levels to 10 years previous.

Genotyping, imputation, QC, and GWAS. In July 2017, UKB released genetic information (directly typed and imputed genotypes) for the entire cohort (n = 487,406) to approved collaborators. Most (90%) of the participants were genotyped on the UKB Axiom Array, with the remaining 10% genotyped on the Affymetrix UK BiLEVE Axiom Array. There is >95% content overlap between arrays. Genotyping, QC, and imputation were performed centrally by UKB and has been previously described (43). Imputation was performed up to combined reference panels from the 1000 Genomes Project (Phase 3), UK10K, and Haplotype Reference Consortium (44). Analyses were restricted to a subset of white British individuals, defined on the basis of self-reported ethnicity and genetic data.

Using UKB data, univariate and multivariate logistic regressions were used to determine covariates to be included in the GWAS analysis. Variables only available for the entire cohort and implicated in previous research were considered, and any values >4 SDs from the mean were removed (n = 7649 participants removed due to missing data). Variables reaching P < 0.01 in separate univariate analysis were carried forward to a multivariate model, where the stepAIC function of the MASS R package was used to determine stepwise entry of variables into the model. Collinearity was determined using variance inflation factor, and variables were accordingly removed from the final model (Variance Inflation Factor >10). An a priori decision was made to include age and sex in all models. Our rationale for using this approach is twofold: first, to account for confounding factors that may bias effect estimates, and second, to improve power by reducing residual variance.

Genetic association analysis in autosomes was conducted using a linear mixed model in BOLT-LMM v2.3.1 (45), adjusted for age at recruitment, sex, genotyping array, and nongenetic covariates identified in the logistic regression model. The BOLT-LMM model includes a random effect derived from a genetic relationship matrix to account for population structure and relatedness. Potential P value inflation due to residual population structure and relatedness was checked using genomic control following filtering of variants based on imputation quality (INFO 0.4) and minor allele frequency of 0.005. Distance-based clustering was used for defining loci, such that genome-wide significant SNPs were ranked from most significant to least significant, and SNPs were retained if they did not map 500 kb of a more significant SNP. Variants reaching P < 5 106 and surviving distance-based clustering (i.e., lead SNPs) in the UKB cohort were explored in the GERA cohort for the purposes of replication.

The GERA cohort was used for replication. GERA is part of the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and has been described in detail elsewhere (46). In short, the cohort comprises 110,266 adult men and women who are consented participants in the RPGEH, an unselected cohort of adult participants who are members of Kaiser Permanente Northern California, an integrated health care delivery system. All study procedures were approved by the Institutional Review Board of the Kaiser Foundation Research Institute.

For this replication analysis, 47,967 GERA participants of non-Hispanic white ethnicity who had alcohol consumption information were included. Alcoholic drinks consumed per week as a quantitative trait (drinks/week) was assessed on the basis of the RPGEH survey as previously described (12) and as part of the Supplementary Materials. Genotyping using Affymetrix Axiom arrays (Affymetrix, Santa Clara, CA, USA) (47, 48), imputation using the cosmopolitan 1000 Genomes Project reference panel, and GWAS analysis were undertaken as detailed in the Supplementary Materials.

METAL was used to perform a fixed-effects meta-analysis between the UKB and GERA cohorts using Stouffers method to account for the effect sizes in discovery and replication being on different scales (49). An overall z-statistic and P value were calculated from a weighted sum of the individual statistics. Weights are proportional to the square root of the number of individuals examined in each sample and selected such that the squared weights sum to 1.0.

A validated association was defined as follows: (i) reaching P < 5 106 in the discovery cohort, (ii) demonstrating nominal association with the same direction of effect in the replication cohort, and (iii) meeting genome-wide significance in the meta-analysis of both datasets sets.

Conditional analysis was performed on validated associations using Genome-wide Complex Trait Analysis (50) (http://cnsgenomics.com/software/gcta/) and the GWAS outcomes from the UKB to identify independent signals in the same region as each lead SNP (500 kb); one model was fitted per region. A set of 5000 randomly selected UKB white British participants was used to develop a reference set to approximate LD. A threshold of P < 1 105 was used to select index SNPs for independent signals in each region, where the conditional estimates were derived from fitting all independent SNPs jointly (i.e., joint model).

Expression quantitative trait loci. The GTEx Portal (http://www.gtexportal.org) was used to assess whether the lead SNP at each locus was an eQTL for local genes across the range of available tissues (51). This approach uses gene expression information across various human tissue types and genotype data to build information on eQTLs using a 1-Mb cis-window around the transcription start site. All tissue types with more than 70 samples available within GTEx were evaluated in our analysis including the brain, heart, liver, skeletal muscle, and skin. Significant eQTLs were based on a false discovery rate (FDR < 0.05) correction. The LD between the top eQTL SNP for any eQTL signal and the GWAS SNP was assessed to explore whether the two signals colocalize with each other; an LD r2 > 0.8 in Europeans from the 1000 Genomes was considered evidence of colocalization.

Genetic correlations. LD Hub v1.9.0 (http://ldsc.broadinstitute.org/ldhub/) was used to identify genetic correlations through LD score regression between the binary alcohol phenotype and other complex traits (52). This method uses individual SNP allele effect sizes from GWAS summary statistics and the average LD in a region to estimate bivariate genetic correlations. We tested for genetic overlap between alcohol consumption from our GWAS and disease outcomes and related traits in European cohorts available in the LD Hub, except for UKB outcomes and metabolites due to the large number of potential comparisons. FDR < 0.05 was used to account for multiple comparisons.

Mendelian randomization. MR-Base v0.4.21 was used for performing two-sample MR to explore the causal relationship between alcohol consumption and other disease outcomes and related traits (53). Outcomes were selected from the NHGRI-EBI GWAS catalog and filtered for European ancestryonly populations. All genome-wide significant SNPs were initially considered. Before MR analysis, the identified SNPs were explored for independence using estimated LD scores from the 1000 Genomes Project European sample, where r2 0.001 among SNPs in a 10,000-kb region resulted in only the SNP with the lowest P value being retained. One hundred eleven outcomes were selected on the basis of being diseases of interest, metabolites influenced by alcohol and prominent in subsequent alcohol-related disease onset or progression (e.g., triglycerides), or other consequences of heavy alcohol consumption. Harmonization between exposure data and outcome data was undertaken to ensure effects corresponded to the same allele. Causal estimates between exposure and outcomes were obtained using the two-sample MR IVW method with FDR for multiple comparisons. Sensitivity analyses to account for pleiotropy were performed using MR-Egger regression and weighted median approaches. The weighted median test has been suggested as an alternative to the MR-Egger when the instrumental variable contains a small number of SNPs.

PheWAS. Gene ATLAS (http://geneatlas.roslin.ed.ac.uk/) was used as a lookup for outcomes from PheWAS analysis performed on UKB traits (54). The database contains data from >450,000 white British individuals, >31 million variants, and 778 traits; only ICD-10 traits were considered (n = 496). This information was used to derive a phenome-wide significance threshold, divided by the number of independent tests, i.e., 1.68 105 [0.05/(496*6)].

Pathway analysis. Reactome pathway knowledgebase (https://reactome.org/) was used to undertake pathway analysis (55). The Reactome Knowledgebase systematically links human proteins to their molecular functions, providing a resource that operates both as an archive of biological processes and as a tool for discovering unexpected functional relationships. Loci identified through distance-based clustering at a relaxed threshold of P < 5 106 from the GWAS analysis were included. These loci were mapped to pathways, and a P value was calculated on the basis of the overlap between the query and the pathway expression; an FDR correction was applied by the software.

C. elegans is an excellent genetic model for investigating whole-animal effects of alcohol (5658). Similar to humans, acute exposure to intoxicating alcohol induces a dose-dependent reduction in coordinated movement of C. elegans both in solution (59) and on solid agar (60). Strains of C. elegans were selected on the basis of the outcomes from the present GWAS at the level of P < 5 108 and having evidence of replication in GERA or being reported as genome-wide significant in other alcohol phenotype studies.

Phenotypic and RNA interference experiments were performed at 20C in a temperature-controlled room on young adult hermaphrodites selected from sparsely populated NGM (nematode growth media) plates. As we and others have previously demonstrated (59, 60), exposure to 400 mM external ethanol reduces coordinated locomotion of wild-type (Bristol N2) animals by ~70%. An external concentration of 400 mM ethanol is equivalent to an internal concentration of ~20 to 70 mM, which is equivalent to a blood alcohol level of ~0.1 to 0.4% and is consistent with levels of intoxication experienced by humans. Locomotion rate was the outcome of interest and was quantified by thrashing in Dents solution [140 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM Hepes (pH 7.4) with bovine serum albumin at 0.1 mg/ml] as previous described (59, 60). See the Supplementary Materials for full details.

All functional data are expressed as means SE. Thirty treated and untreated animals were analyzed and compared per strain per experiment. Statistical significance was assessed by one-way analysis of variance (ANOVA) with post hoc Bonferroni correction for multiple comparisons.

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/6/3/eaay5034/DC1

Supplementary Methods

Table S1. Summary of final multivariable logistic regression model.

Table S2. Summary of genome-wide significant SNPs following distance-based clumping on the UKB cohort, and the replication cohort and meta-analysis outcomes.

Table S3. eQTL analysis outcomes.

Table S4. LD between the top eQTL SNP for any eQTL signal and the GWAS SNP.

Table S5. Variant-trait significant outcomes from PheWAS.

Table S6. Variants at 5 106 and submitted to the Reactome Knowledgebase.

Table S7. Mendelian randomization results for nominally significant outcomes in the IVW analysis and FDR outcomes using the IVW method.

Fig. S1. LocusZoom plots for lead SNPs from GWAS on alcohol phenotype in the entire cohort.

Fig. S2. Constitutive signaling by aberrant PI3K in cancer.

Fig. S3. Individual C. elegans b-Klotho genes outcomes.

References (6171)

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

H. Kranzler, H. Zhou, R. Kember, R. V. Smith, A. Justice, S. Damrauer, P. S. Tsao, D. Klarin, D. J. Rader, Z. Cheng, J. P. Tate, W. C. Becker, J. Concato, K. Xu, R. Polimanti, H. Zhao, J. Gelernter, Genome-wide Association Study of Alcohol Consumption and Use Disorder in Multiple Populations (N = 274,424). bioRxiv 527929v1 [Preprint] (2019).

Acknowledgments: Funding: This work was supported by the Medical Research Council (grant number MR/S000607/1). Genotyping of the GERA cohort was funded by a grant from the National Institute on Aging, National Institute of Mental Health, and National Institute of Health Common Fund (RC2 AG036607). Analysis of GERA data was supported by NIH grants National Eye Institute grants R01 EY027004, R01 DK116738, and R21 AA021223 (E.J.). Author contributions: A.T., A.P.M., and M.P. conceived the project. A.T., J.C., and A.P.M. performed the discovery, replication, and in silico analysis. E.J., H.C., and J.Y. provided access to the replication cohort and data analysis. J.B. and T.K. provided access to C. elegans assays and performed the experiments. A.T., J.C., and J.B. produced data visualization. A.P.M. and M.P. supervised the project. A.T. wrote the original draft. All authors critically reviewed the drafts of the manuscript and approved the final version. Competing interests: The authors declare that they have no competing interests Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The data from UKB were provided under license by UKB, who is the owner of the data. Requests for access to the data should be directed to UKB as per the material transfer agreement. Additional data related to this paper may be requested from the authors.

Read more from the original source:
Functional validity, role, and implications of heavy alcohol consumption genetic loci - Science Advances

Read More...

Healthy Headlines: Four common myths about genetic testing and why they are not accurate – User-generated content

Monday, January 20th, 2020

St. Elizabeth Healthcare

If you could take a simple test that would identify your risks of developing a potentially deadly disease so you could prevent it or treat it sooner, wouldnt you?

A proactive genetic test can do just that. Caroline Ewart, Genetic Counselor in the Center for Precision Medicine and Genomic Health at St. Elizabeth Healthcare, says, Understanding your family tree is important for your future health. Genetics play a big role in what diseases we will develop in the future. The more we understand the family, the more you can proactively do to protect your health.

Many people dont consider genetic testing because they think it is too expensive, not accurate enough, or doesnt screen for the diseases that run in their family. Ewart is helping us bust some of the common myths of genetic testing.

Myth #1: Genetic Testing is Too Expensive

When proactive genetic testing started, it was very expensive, and only a few select laboratories across the country performed the testing. Today, genetic testing is very affordable. Many health insurance companies will provide some coverage for testing, and the laboratories now have a limit on what they can charge.

A proactive screening in the Center for Precision Medicine and Genomic at St. Elizabeth Healthcare is just $395. That includes an initial genetic counseling visit, coordination of blood tests, carrier status screening, and a comprehensive consultation discussing your results. Individuals with a Flexible Spending Account (FSA) or Health Savings Account (HSA) may be able to use these funds to pay for the cost of the screening.

Myth #2: Genetic Testing Only Finds Breast Cancers

Its true, when genetic testing was in its infancy, we only tested for BRCA1 and 2 genes which detect breast and ovarian cancers, says Ewart. But the tests today are far more sophisticated. We now test for over 100 different gene mutations looking for a range of diseases and cancers.

Inherited conditions the tests screen for, include:

Breast cancer

Cardiovascular diseases

Colorectal cancer

Cutaneous melanoma

Gastric cancer

Ovarian cancer

Pancreatic cancer

Renal cell cancer

Thyroid cancer

Myth #3: Genetic Testing Doesnt Help the Treatment of Diseases like Cancer

Genetic testing is used not only to proactively screen for certain diseases, but it is used to treat cancer as well.

If you have been diagnosed with cancer, the gene mutation may guide treatment. It can also help your team manage increased risks of developing other types of cancers, says Ewart.

More importantly, the results of proactive genetic testing can guide your healthcare teams recommendations for screenings of cancer and cardiovascular diseases. This may include starting screenings at an earlier age, increasing the frequency of screenings or suggesting more advance screenings.

By screening early, we can find the disease early, when it is most treatable, says Caroline.

Myth #4: Genetic Testing isnt Accurate

Ewart says, Certainly there are limitations to testing, but our process is more than just a blood test. By gathering a thorough family history we can determine your risk factors for developing certain diseases, even if a blood test comes back negative.

At St. Elizabeth Healthcare, if you are found to be at high risk or test positive for genetic cancers, you are referred to the Heredity Cancer Clinic to develop a plan for future cancer screenings. They may also recommend your family members be tested, so you can get a full picture of your familys health. St. Elizabeth has many types of genetic screenings. To find the one that best fits your needs, pleasestelizabeth.com/dna or call 859-301-GENE (4363).

View original post here:
Healthy Headlines: Four common myths about genetic testing and why they are not accurate - User-generated content

Read More...

18 Amish young people died suddenly; Mayo Clinic identified genetic problem believed to be responsible – LancasterOnline

Monday, January 20th, 2020

The Mayo Clinic has identified a genetic problem believed to have caused sudden death in 18 of 23 Amish young people who had it, according to media reports.

The study published recently in JAMA Cardiology said researchers studied two large Amish extended families that reported multiple sudden deaths, including four siblings with exercise-associated sudden deaths.

"With the help of new technology that wasn't around when they first started looking into the case, the team learned that these Amish children had all inherited the same genetic mutation from both of their parent," CNN reported.

Now that the problem has been identified, Popular Science reported, potential couples can be tested to see whether they are both carriers, and people who are at risk of sudden death because of the problem can have a defibrillator implanted.

One of the best-known medical facilities working with the Amish and other Plain community people to identify and treat genetic diseases is in Lancaster County the Clinic for Special Children in Strasburg.

The clinic wasn't involved in the study, according to spokeswoman Kelly Cullen. However, she said, lab director Dr. Erik Puffenberger checked its thousands of records for RYR2, the gene involved. None were affected, she wrote, only three were carriers of the gene, and only one of those people was local to Lancaster County, "demonstrating that the RYR2 genetic variant is very rare in our area."

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

However, she wrote, the clinic is planning to add RYR2 to the next version of its Plain Insight Panel, which screens for thousands of genetic variants known to cause problems across the Plain communities of North America.

See the article here:
18 Amish young people died suddenly; Mayo Clinic identified genetic problem believed to be responsible - LancasterOnline

Read More...

The Case Of Pamela Maurers Murder Went Cold For Decades, Then Genetic Sleuthing By Parabon Helped Crack It – CBS Chicago

Monday, January 20th, 2020

CHICAGO (CBS) Despite exhaustive work by detectives, the murder of Pamela Maurer was left unsolved for more than four decades. Last year, a relatively new form of genetic sleuthing began to put together the pieces of the mystery in a matter of days.

DuPage County investigators provided genetic material preserved from the Maurer crime scene to Maryland-based Parabon NanoLabs. Pamelas body was found in Lisle in January of 1976. She had been sexually assaulted and strangled. She was last seen alive the night before her body was found, when she told friends she was going to a restaurant to buy a soft drink.

First, Parabon, led by chief genetic genealogist CeCe Moore, used the DNA to create a snapshot genotypewhich predicts a persons physical traits, such as eye, skin and hair color, and even the shape of a face.

The composite created from that test looks remarkably similar to Bruce Lindahl, a suspected serial killer who police now say killed Maurer. Lindahl died in 1981.

But the testing didnt stop with just a picture. The hard work had only just begun.

Moores team used the DNA to reverse engineer Lindahls family tree.

Parabon loaded the DNA sample from the Maurer crime to a website called GEDmatch and began a form of genetic treasure hunting. GEDMatch is a site where users can upload their genetic testing results, done by companies like 23AndMe and Ancestry.

Typically, Moore said, they find similar DNA from distant cousins of a suspect and build back from there.

We are looking just for people who are second, third, fourth, fifth cousins and beyond, Moore said. Typically we are not getting close matches to close family members.

Basically, Parabon is reverse engineering the family tree of the suspect based on who they are sharing DNA with, Moore said.

Moore said she found multiple distant cousins that led to Lindahl, up to 20 matches and put those puzzle pieces together.

It is almost never a single match that leads to an identity. Its a group of matches to see how they all connect to each other.

My work, and my teams work is really about providing answers to these families for years and decades, Moore said.

She said part of the hunt is luck. In this case, the data allowed them to find a suspected match to Lindahl in a few days.

But Parabons work didnt solve the case. Detectives still needed more proof. So, they got a court order to exhume Lindahls body and extract DNA from his remains.

The result was a match.

The odds of the DNA belonging to somebody else are 1 in 1.8 quadrillion, DuPage County States Attorney Robert Berlin said this week.

This was the second case Parabon has done in Illinois, but the first in the Chicago area.

Last year, Moores work led to murder charges against Michael Henslick, who police say killed Holly Cassano. She was found fatally stabbed in her home in Mahomet, Ill., on Nov. 2, 2009.

That case is expected to go to trial next month, Moore said. Parabon has so far worked on 93 cases with police across the country in the past two years. The most famous charges against the suspected Golden State Killer, Joseph James DeAngelo.

Critics find the practice controversial and a potential invasion of private DNA data. Moore says the benefit to the public, ensuring that killers are put behind bars, and the fact that families get some resolution, far outweigh those concerns.

I feel that the good that has been done is really immeasurable to public safety, Moore said.

Lindahl died at age 28 in 1981 after he bled to death while stabbing another victim, Charles Huber. The coroner said his knife wounds were accidentally self inflicted.

RELATED: Those Who Remember Lindahl Say He Gave Them The Creeps

Police now say he may have killed at least two other women.

Lindahl was charged with raping Deborah Colliander, who manged to escape from the attack. However, two weeks before Lindahls trial, Colliander disappeared after leaving her job at a hospital.

The case against Lindahl was dropped.Collianders body was found on April 28, 1982in a field on Oswego Township.

Investigators also think Lindahl may have something to do with the disappearance of Deborah McCall, a student at Downers Grove North. She was last seen alive in November 1979. Photos of her were found in one of Lindahls residences.

And there may be other victims in the 1970s and before his death, police said. The new evidence will be used to open additional investigations.

Investigators set up two tip lines: (630) 407-8107 (DuPage States Attorney) and (630) 271-4252 (Lisle police).

Read the rest here:
The Case Of Pamela Maurers Murder Went Cold For Decades, Then Genetic Sleuthing By Parabon Helped Crack It - CBS Chicago

Read More...

Donor-conceived people lobby UN for access to their genetic heritage – UNSW Newsroom

Monday, January 20th, 2020

Giselle Newton, a PhD research student at UNSW, is one of 16 donor-conceived and surrogate-born people from around the world who are leading a renewed push to change laws which govern their access to information about their genetic heritage.

For the first time, the group told their own stories at a historic visit to the United Nations to mark the 30-year anniversary of the Convention for the Rights of the Child in Geneva on November 19.

They presented their five recommendations* to the Human Rights High Commissioner Michele Bachelet, and received a standing ovation from the audience.

We highlighted the consequences of ignoring the voices of those most affected by these practices, Ms Newton says. Donor-conceived people are experts on this issue and our voices need to be listened to and acted upon.

International Social Services representative Mia Dambach led the workshop on biotechnology at the UN, and says there is an urgent need for the development of global standards.

It is hoped that this will not be the last time the voices of those most affected are heard representing as many experiences as possible, Ms Dambach says.

Ms Newton was conceived in the Northern Territory by sperm donated in Western Australia, before being born in NSW.

She says her parents did the right thing by telling her at a very young age that she was donor-conceived.

From day dot, its really important for children to know they were donor-conceived, Ms Newton says. And that they have the ability to contact donors and donor-conceived siblings.

Laws

In Australia, laws differ between the states.Victoria is leading with legislation implemented in 2017 that allows all donor-conceived people the chance to retrospectively access information about their biological parents.

It would be good if other states really pull up their socks and follow suit, Ms Newton says.

But in NSW, recent changes to legislation allow donor-conceived children born after January 1, 2010 the ability to track down their biological parent(s), once they turn 18. Those born before this date can only access non-identifying markers such as the ethnicity, physical characteristics, medical history, and the sex and year of each of the donors offspring.

In WA, once a donor child turns 16, records relating to his or her lineage are open for them to access. But for those born before 2004, they need to have the donors permission before they can obtain the missing pieces to their biological puzzle.

What Ms Newton and others like her want is the power to access information about their identity and origins including information about their donors and donor-conceived siblings.Being disconnected from your biological history can have drastic consequences in terms of identity, she says.

It is this emotional element that US doctor William Pancoast did not foresee when he made the first successful experiment by artificially inseminating a woman with the sperm of one of his most attractive medical students in 1866.

UNSW PhD study

While estimates have suggested that there are between 20,000-60,000 donor-conceived people in Australia, Ms Newton says that there has been very limited empirical research that explores life as a donor-conceived adult in Australia.

In her doctoral thesis at UNSWs Centre for Social Research in Health, she will examine what services and support are available to donor-conceived people with a particular focus on the role of peer support in online and offline contexts.

I am really fascinated by the idea of how connection with peers can contribute to a sense of belonging, she says.

UNSW Associate Professor Christy Newman has highlighted the importance of Ms Newtons research for the support needs of donor-conceived adults. She hopes it will help inform policy and practice responses to this increasingly growing group of people in Australia and around the world.

Ms Newton will be recruiting donor-conceived people to participate in a national online survey and interviews in early 2020.

(To participate or find out more about the study)

An international concern

Netherlands-based Joey Hoofdman was among those who participated at the UN conference in Geneva. Mr Hoofdman found out he has at least 75 half-siblings via the doctor who treated his parents for fertility problems in the 1980s. The 32-year-old only discovered in 2017 that he was donor-conceived.

Mr Hoofdman says he blames his biological father for having crossed a medical-ethical boundary by using his own sperm during a time when there was insufficient supervision and a lack of regulation.

We need to make agreements on an international level so we can prevent this from ever happening again.

*Recommendations

Ms Newton, Mr Hoofdman and others put forward the following to the UN:

1) Ensure the right of donor-conceived and surrogate-born children to access information about their identity and origins regardless of when these children were conceived and born, and to preserve relations with their biological, social and gestational families.

2) Ensure that comprehensive and complete records of all parties involved in the conception of the child be held by the State in perpetuity for future generations.

3) Respect and promote the full and effective enjoyment of all the rights of donor-conceived and surrogate-born children in both the immediate and longer terms.

4) Ensure that the best interests of the child be the paramount consideration in all relevant laws, policies and practices and in any judicial and administrative decisions. This requires a best interests assessment pre-conception on a case-by-case basis.

5) Prohibit all forms of commercialisation of gametes, children and surrogates including, but not limited to, the sale and trafficking in persons and gametes.

Go here to see the original:
Donor-conceived people lobby UN for access to their genetic heritage - UNSW Newsroom

Read More...

BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO – Siliconrepublic.com

Monday, January 20th, 2020

We visited theBT Young Scientist and Technology Exhibition again this year, getting the chance to chat to some of the countrys brightest students.

There were project posters stretching to all corners of the main hall at the RDS, filled with excited participants waiting for their visit from the judging panel.

Hugh Murtagh from Coliste Mhuire in Westmeath took us through hisA-Ok project a discreet wristband that students with autism can wear to let their teacher know if theyre feeling overwhelmed at school.

I have autism and I know just how hard it is to try and focus in class when you feel overwhelmed. I want to try and help people like me and people who also have autism, he said.

We also learned about an eco-powered dollhouse with the potential to teach children about climate action, how mental health can be impacted by climate change, and whether genetics affects how clever a dog breed is.

>> READ MORE

Words by Lisa Ardill

More:
BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO - Siliconrepublic.com

Read More...

Personalized nutrition could be the next plant-based meat, worth $64 billion by 2040, says UBS – CNBC

Monday, January 20th, 2020

Imagine receiving customized nutrition advice based on your personal biologic or genetic profile. That's the "future of food," according to a UBS analyst, who sees diet personalization as the next plant-based meat.

Personalized nutrition could generate annual revenues as high as $64 billion by 2040, the firm said. Plus, big-name companies such asApple, Uber and Amazon could benefit from the massive growth opportunity.

"With heightened health awareness among consumers, yet also more people suffering from ailments which are attributable to poor nutrition, there is growing demand for solutions that can improve individual nutritional choices," said UBS analyst Charles Eden in a note to clients on Tuesday. "Personalised nutrition ... represents a potential such solution."

Personalization is a theme that has swept many industries in recent years. An increasing number of businesses are sending out questionnaires to customers to create profiles for their likes, dislikes and needs. Customized weight loss programs, clothing and shopping companies, makeup brands, vitamin providers, are just a few to have delved into an industry with massive growth potential, said Eden.

UBS's theory is that food, medical diagnosis, technology and food delivery companies can all benefit from this industry. From services as simple as questionnaires, blood samples and genetic profiling, companies can capitalize on society's shift in support to improved nutritional habits.

UBS said it sees four major industries capitalizing on this opportunity: Medical diagnosis firms to extract and interpret test results; Technology companies to develop wearable tech and integrated platforms for users to receive ongoing interactive feedback; Food producers to meet nutritional demand; And, food delivery companies to meet consumers' increasing demand for convenience.

Illumina, Thermo Fisher Scientific, Apple, FitBit, Nestle, 23andMe, Ancestry.com, Unilever, Amazon Fresh and Uber Eats are some of the companies UBS mentioned as being in the game.

The personalized nutrition opportunity has not been lost on current food company incumbents.

"Nestl, the world's largest food company, has identified personalised nutrition as a major growth opportunity and has made a number of investments in the space," said Eden.

Nestle puts money into research from brain health, pediatrics, chronic medical conditions, obesity, malnutrition, and gastro-intestinal health.

Companies like Apple have bet big on personalized health, which could make the Tim Cook-led tech giant a potential pioneer in the personalized nutrition industry. Apple has identified the health care industry as an area of innovation, with its popular Apple Watch providing real-time personal health data to its wearers.

"The Apple Watch is already being used to study heart rates, perform ECGs, study eating disorders, track fitness and many other health metrics. Health data in Apple Watch could be combined with genetic information to offer personalized nutrition," said Eden.

Even Amazon Fresh, the e-commerce giant's grocery delivery service, and Uber Eats are well-positioned to win in this budding industry, said UBS.

"Delivery will allow for increased convenience and time savings in food preparation (e.g. partnering with Delivery Hero or Uber Eats to deliver the exact meal which has been freshly prepared to meet the needs of that individual consumer)," said Eden.

Eden said affordability is the most obvious constraint on the personalized nutrition scenario in the near term. Healthier foods can be more expensive than mass produced box items, and the personalization will also come with a cost.

Scientific evidence on the merits of personalizaiton are also lacking, UBS said.

Data privacy is a hurdle as well if consumers don't want their medical, biological or genetic information shared with other parties.

with reporting from CNBC's Michael Bloom.

Continued here:
Personalized nutrition could be the next plant-based meat, worth $64 billion by 2040, says UBS - CNBC

Read More...

Access And Actionability Are Key For Genetic Testing And Precision Medicine – Forbes

Wednesday, January 15th, 2020

Over the past two decades, the field of medical genomics underwent nothing less than a revolution in terms of both technological advancement and accumulated knowledge. This revolution holds the promise of changing the entire medical practice, and while the industrycontinues to improve genome sequencing technologies and decrease the price of sequencing a genome, other challenges are lurking that hinder the prospects of this revolution and undermine the efforts of wide-scale integration of genomics into mainstream medicine.

To emphasize this point further, even though the technologies to help diagnose patients with rare genetic diseases exist, the rate of underdiagnoses and misdiagnoses is still alarmingly high, and patients who receive diagnoses end up waiting too long for them, sometimes years. These extensive diagnostic journeys directly impact the ability to recruit patients for clinical trials, and thus the ability to develop more treatments for rare diseases. To date, only 5% of more than 7,000 known rare genetic diseases have FDA-approved treatments.

At my company, a leading digital health company, our mission is to end the diagnostic odyssey for undiagnosed pediatric patients with rare diseases. I've seen that the main contributors to this state of affairs are the excruciatingly long wait times for genetics appointments, coupled with the significant workforce shortage of experts in the field.

To reach more than 400 million patients globally (50% of whom are estimated to be young kids) with earlier intervention to improve outcomes and help many of them live relatively healthy and productive lives, the diagnosis must shift from the geneticists clinic to the primary point of care, or at least it must be initiated much earlier by primary care physicians.

Without adopting technological solutions that will support the integration of genomics into mainstream medicine, genomics will never live up to its promise and become a standard of care. In my opinion, realizing that vision will be a balancing act between the affordability for payers, accessibility for providers and actionability for patients, and it will depend on technological solutions combining AI-based phenotyping, as well as connecting front-line providers with human experts in genetics, alongside the most advanced genome sequencing technologies.

High Throughput Genetic Testing

As noted, genome sequencing technologies have made huge strides over the last two decades. The affordability of genomics is now increasingly dependent on the ability to sift through and interpret vast amounts of data produced from a genome, and to determine which data is pertinent for a medical diagnosis and for disease treatment a task fitting for AI.

Indeed, in the last few years, we have witnessed many AI-driven solutions sprouting to address this problem. Some of these solutions are home-grown, in leading laboratories such as Invitae, GeneDx and PerkinElmer Genomics. (Full disclosure: PerkinElmer Genomics uses FDNA's technology in its genetic analysis.) Others are developed as software platforms by vendors such as Sophia Genetics, Fabric Genomics, Congenica and Emedgene.

Harnessing AI to perform data analysis challenges has proven to be very successful and is a direct contributor to the affordability of genetic testing today, as well as the gradually increasing rate of reimbursement by payers. I believe AI will continue to play a key role in driving down prices to the $100 range, which will make genomics extremely affordable, both for health systems and for individuals paying out-of-pocket.

Phenotyping Driven By AI

AIs impact goes far beyond applying machine learning algorithms that sift through genetic variations and proprietary knowledge bases of pathogenicity. As more OMICS technologies stack up with genomics, and more AI modalities like natural language processing and computer vision image analysis are integrated directly into the genome analysis pipeline, we will see an increasing standardization of data across disparate data silos and a closing of the genotype-phenotype gap between the clinic and the lab. This trend will drive genomic data to become more actionable for patients and allow them to make informed decisions about their health.

Much of todays phenotyping is performed by humans and is inherently subject to biases such as age, gender and ethnicity. If we approach this problem with legal and ethical rigor, care and are cautious of patient privacy, and with respect to the providers and their workflow, AI could enhance human skills and capabilities. I think that helping primary care providers collect, structure and analyze phenotypic information of patients with rare diseases is an area worth prioritizing.

Connecting The Expert Community

Finally, technology is more than AI. Technology is also an enabler for fostering connections and interactions between humans. Some tasks in practicing medicine must be left to humans, but even then, technology can assist. An alternative abbreviation of AI (augmented intelligence) is my preferred one. It implies a symbiotic relationship between people and machines, making each other stronger, rather than threatening to replace each other.

Tailoring a solution combining all three components (genomics, AI-based phenotyping and community connection) like the one described above is not an easy task, and it depends on the ability of stakeholders from many disciplines to work together, share data and collaborate on research and development.

To achieve this, a best-of-breed approach should be taken, and not only should data be shared, but a global collaboration between commercial companies, academic research institutions and caregivers should occur. The integrity of the data, ethical and privacy policies, and trust in workflow should be established. This requires an open dialogue between all parties involved, as well as a fast-pace framework to allow developers to move quickly in building these tools.

Certainly, working with different stakeholders with sometimes conflicting interests is challenging, but the one common goal we all have is helping patients, especially kids with rare and undiagnosed genetic diseases.

Read more from the original source:
Access And Actionability Are Key For Genetic Testing And Precision Medicine - Forbes

Read More...

Cleveland Clinic Study Identifies Genetic Anomaly Associated with Poor Response to Common Asthma Treatment – Health Essentials from Cleveland Clinic

Wednesday, January 15th, 2020

Nima Sharifi, M.D.

A new Cleveland Clinic study has uncovered a genetic anomaly associated with poor response to a common asthma treatment. The findings, published in Proceedings of the National Academy of Sciences, showed that asthmatic patients with the gene variant are less likely to respond to glucocorticoids and often develop severe asthma.

The research team, led by Nima Sharifi, M.D., of Cleveland Clinics Lerner Research Institute, identified that the gene variant HSD3B1(1245A) is associated with glucocorticoid response and may be clinically useful to identify patients most likely to benefit from other treatments.

Glucocorticoids, which modulate systemic inflammatory response, are commonly prescribed to treat severe asthma. However, until now we have not understood why many patients do not benefit from them, said Dr. Sharifi, senior author of the article. These findings make the case for genetic testing and personalized treatment and provide important information for identifying which patients should be treated using different therapies.

In the study, Dr. Sharifi and his collaborators retrospectively analyzed the association between patient genomes and lung function in more than 500 asthmatic patients who received daily oral glucocorticoids treatment or no glucocorticoids treatment.

Joe Zein, M.D.

They found that a change to the gene HSD3B1 specifically the HSD3B1(1245A) variant is associated with poor lung function and glucocorticoid treatment resistance. The analysis revealed that among patients receiving glucocorticoids, those with the variant had poorer lung function than those who did not have the genetic anomaly, suggesting that it contributes to resistance and helps drive the progression to severe asthma.

Previous studies have shown that HSD3B1 encodes an enzyme that converts less active hormones called androgens into more powerful androgens. While additional research is necessary, the team suspects that HSD3B1(1245A)s effect on lung function may be attributed to inhibition of this process.

This study is the first to provide genetic evidence suggesting that variants related to androgen synthesis affect glucocorticoids treatment resistance in asthma or any other inflammation-related disease, said Joe Zein, M.D., first author on the study and a practicing pulmonologist in Cleveland Clinics Respiratory Institute. These findings provide us with important new information that may lead to more tailored treatments for asthma patients and the ability to prevent the development of severe disease.

Asthma is a chronic condition that causes the airways of the lungs to narrow, the lining of the airways to become inflamed and the cells that line the airways to produce more mucus, making it difficult to take in enough air. According to the CDC, about 25 million people in the U.S. have asthma, including more than six million children. Asthma accounts for nearly two million emergency department visits each year.

Previously, Dr. Sharifis laboratory has extensively studied the role of HSD3B1 in prostate cancer. In 2013, he made the seminal discovery that prostate cancer cells with the HSD3B1(1245C) variant survive androgen deprivation therapy, the first line of defense against prostate cancer, by producing their own disease-fueling androgens. He has spent more than seven years studying and publishing peer-reviewed articles on the variants effect in prostate cancer.

Dr. Sharifi holds the Kendrick Family Chair for Prostate Cancer Research at Cleveland Clinic and directs the Cleveland Clinic Genitourinary Malignancies Research Center. He has joint appointments in the Glickman Urological & Kidney Institute and Taussig Cancer Institute. In 2017, he received the national Top Ten Clinical Achievement Award from the Clinical Research Forum for his discoveries linking HSD3B1(1245C) with poor prostate cancer outcomes.

Dr. Zein is a member of the Cleveland Clinic Asthma Center, which provides a comprehensive approach to asthma management and care along with innovative research, offering patients access to the most advanced diagnostic testing and innovative treatments.

This study was supported by the National Heart, Lung, and Blood Institute and the National Cancer Institute, both of the National Institutes of Health.

Link:
Cleveland Clinic Study Identifies Genetic Anomaly Associated with Poor Response to Common Asthma Treatment - Health Essentials from Cleveland Clinic

Read More...

Scientists discover six genetic links to anxiety – The Hill

Wednesday, January 15th, 2020

Researchers say theyve discovered six genetic variants associated with the development of anxiety disorders in what they call the largest study of anxiety traits.

In a study published Tuesday in the American Journal of Psychiatry, researchers examined genetic and health data from 200,000 U.S. veterans. The data was compiled by the Million Veteran Program, a research groupfunded by the federal government to determine how genes, lifestyle and military exposures affect health and illness.

While there have been many studies on the genetic basis of depression, far fewer have looked for variants linked to anxiety, disorders of which afflict as many as 1 in 10 Americans, Murray Stein, a staff psychiatrist in the VA San Diego Healthcare System, said in a statement.

In the analysis, researchers discovered six genetic variants associated with higher risks of developing anxiety disorders. The variants related to anxiety disorders were found on chromosomes 1, 3, 6, 7 and 20. The studys authors called it an important step forward in understanding how genes contribute to mental conditions.

The variant on chromosome 7 is identified to be correlated with higher occurrences of bipolar disorder and schizophrenia.

Its also associated with the reception of estrogen, but researchers were reluctant to draw the conclusion on whether that could explain why women are twice as likely than men to be affected by anxiety disorders. While female veterans were included in the study, more than 90 percent of the participants were men. The studys authors said more research is needed on the topic.

The study also found that five of the genetic variants were found in white Americans, while an additional variant was found in African Americans.

Minorities are underrepresented in genetic studies, and the diversity of the Million Veteran Program was essential for this part of the project, Dan Levey, of the VA Connecticut Healthcare Center and Yale University, said in a statement.The genetic variant we identified occurs only in individuals of African ancestry, and would have been completely missed in less diverse cohorts.

According to the Anxiety and Depression Association of America, almost 40 million people in the U.S. experience an anxiety disorder in any given year.

See original here:
Scientists discover six genetic links to anxiety - The Hill

Read More...

Co-Diagnostics" genetic detection technology on display at international agriculture conference – Proactive Investors USA & Canada

Wednesday, January 15th, 2020

A presentation by a Bayer Crop Science rep described the company's successful Multiplex PCR genetic detection

Incs () BHQplex CoPrimer technology, which is used in diagnostics tests utilizing DNA or RNA, was the star of a presentation from Bayer Crop Science at an agricultural presentation on Tuesday.

The presentation, titled "CoPrimer Assays for Multiplex PCR," was put on by a Bayer representative at the International Plant & Animal Genome XXVIII conference this weekin San Diego.

It described a study that involved developing genotyping assays which detect genetic sequences using the Utah-based companys CoPrimer technology. That detection process includes includes multiplex PCR (polymerase chain reaction), a system for detecting multiple genetic sequences all at once, rather than having to do a new test for each particular sequence.

"We are excited to announce this third-party validation, the importance of which cannot be overstated, and which further supports our confidence in the uniqueness and superior advantages of our patented CoPrimer platform technology, CEO Dwight Egan said in a statement. Bayers commitment to a world where more sustainable farming practices and more adaptive, resilient plants are part of the solution to making hunger a thing of the past aligns perfectly with our mission to improve the lives and quality of life in communities across the world.

Co-Diagnostics technology is being licensed by LGC Biosearch Technologies, a biotechnology company based in the UK.

"With partners like LGC, including their globe-spanning footprint in over 200 countries, and validation from such an important force in the world of agriculture as Bayer, we believe that Co-Diagnostics is better positioned than ever to leverage our technology platform and establishing the Company as a valuable player in the world of AgBio, Egan said.

Contact Andrew Kessel at [emailprotected]

Follow him on Twitter @andrew_kessel

See original here:
Co-Diagnostics" genetic detection technology on display at international agriculture conference - Proactive Investors USA & Canada

Read More...

Wiping out scrapie in goats, the genetic way – Fence Post

Wednesday, January 15th, 2020

More consumers are developing a taste for goat cheese, milk, and meat as they become aware of the high protein and great taste of these products. While U.S. goat producers are enjoying this steady trend, they remain focused on keeping their animals healthy, especially from scrapie a fatal brain disease that affects goats and sheep.

The goat industry is one of the fastest growing animal industries in agriculture, said Stephen White, an Agricultural Research Service geneticist. Not too many years ago, there were only a few hundred thousand goats in the country. But in January 2018, goats and kids totaled 2.62 million head.

Meat and dairy are the biggest markets, followed by mohair, but goats serve in other unique capacities, said ARS veterinary medical officer David Schneider. Goats are being used to manage weedy areas along highways, get rid of kudzu in the Southeast, and even mow lawns. Theyre also used as pack animals to carry supplies through rugged areas.

For any of these businesses, a single outbreak of scrapie could be devastating.

There is no cure or treatment for scrapie, which is in the same family transmissible spongiform encephalopathies (TSEs) or prion diseases as mad cow disease. TSEs are rare degenerative brain disorders characterized by tiny holes that give the brain a spongy appearance.

Most often scrapie is transmitted through birth fluids to other goats and sheep, and it can remain infectious in the environment for many years. It was first recognized in sheep in Great Britain and other European countries more than 250 years ago and was first diagnosed in U.S. sheep in 1947 in a Michigan flock.

All animals that get scrapie die. But there is good news from ARS. White and Schneider, who both work at ARSs Animal Disease Research Unit in Pullman, Wash., are the first to demonstrate by infectious disease challenge that goats with the S146 allele (a different form of a gene) are less susceptible to scrapie over a usual goat lifetime. They also tested the K222 allele in goats. Their research shows that goats with one copy of either the S146 or K222 allele did not develop scrapie after being challenged with infection at birth. The study was published in The Veterinary Journal in 2018.

Commercial goats raised for either meat or milk age out of herd participation as milkers, dams of commercial offspring, or as sires by around 6 years of age, White said. In this ongoing ARS research, goats with the resistance alleles have lived beyond this commercial lifetime up to 7 years with no clinical disease and without getting sick.

The only countries considered to be scrapie free are Australia and New Zealand. Currently, if one goat is diagnosed with scrapie on a U.S. farm, all goats are quarantined for life or euthanized. You couldnt restock your operation with any susceptible animal, White said. The farmers operation would be over.

This research is good news for both goat and sheep producers because it could help with eradication efforts. Before U.S. producers can take advantage of import and export markets, scrapie must be eradicated from the United States and meet the World Organisation for Animal Health (OIE) criteria for disease freedom.

I think for the sheep industry alone, thats about $10 to $20 million annually in lost revenue, Schneider said.

ERADICATION EFFORTS

The U.S. Department of Agricultures Animal and Plant Health Inspection Service heads the National Scrapie Eradication Program. The agency reports that the prevalence of scrapie has decreased significantly since 2002 through eradication efforts. According to OIE rules, to be declared free of scrapie a country must conduct extensive surveillance for the disease and have had no scrapie cases for seven years, Schneider said.

In sheep, genetic resistance was discovered years ago. A test was then developed to allow U.S. sheep producers to test flocks and breed for the resistance allele. Now if theres a scrapie outbreak on a farm, sheep that have the resistant genotype do not have to be quarantine or euthanized.

The goat industry is hoping that APHIS will recognize the S146 and K222 genetic alleles and give the resistance goats the same get out of jail card that sheep have, White said.

In 2007, White and Schneider started their study by challenging goat kids at birth with a mega dose of scrapie. The ongoing study consists of three genotype groups: goats with the protective S146 allele, goats with the K222 allele, and a control group with the common U.S. goat allele.

Most of the goats with the S146 or K222 allele lived a very long time and did not contract scrapie. Those that died were euthanized due to other natural causes. In contrast, all animals in the control group got scrapie within two years.

The S146 and K222 alleles had previously been associated with scrapie resistance in goats, but resistance to challenge had not been scientifically demonstrated, White said. Were the only ones, to our knowledge, testing these alleles for scrapie resistance to challenge with scrapie from anywhere in the Western Hemisphere. Also, our research is one of the longest running studies, he added.

In 2016, the U.S. Animal Health Association passed a resolution declaring that the evidence for these two alleles is compelling and should be incorporated into the scrapie eradication program, White said. Last year, a European Food Safety Authority panel of scrapie experts determined that there was enough evidence for the two alleles, plus a third known as D146, to be considered resistance alleles for classical scrapie in goats. The panel, which cited ARS research, concluded that these are resistance alleles and recommended they be used in scrapie control and eradication programs.

A DNA test was developed to identify animals with the S146 and K222 alleles and became commercially available in 2018. ARS scientists did not develop the test, but they played a major role in making sure it worked and helping to get it to the goat industry.

This ARS research is a definitive demonstration of goat scrapie resistance, Schneider said. Its important to farmers, their networks, the goat and sheep industries, and other countries with goat scrapie problems.

We have a long-time cooperation with the Canadian Food Inspection Agency, Schneider said. Weve been asked to help them with their in-house testing so they can apply the data to their scrapie eradication program.

Scientists continue to study the goats in the project to find out how long theyll live. This is ARS making an impact serving a role in long-term experiments that only ARS can and its happening now, Schneider said.By Sandra Avant, formerly with ARS Office of Communications.

Go here to see the original:
Wiping out scrapie in goats, the genetic way - Fence Post

Read More...

High Genetic Risk Score Associated With Organ Damage, Renal Dysfunction, and All-Cause Mortality in SLE – Rheumatology Advisor

Wednesday, January 15th, 2020

High genetic risk score (GRS) may predict organ damage, end-stage renal disease, and all-cause mortality in patients with systemic lupus erythematosus (SLE), according to study results published in Annals of Rheumatic Disease.1

Investigators genotyped data of a discovery cohort and a replication cohort that included patients with SLE and healthy controls. Patients with SLE (n=1001) were enrolled in the discovery cohort from various clinics in Sweden; healthy controls (n=2802) were enrolled from blood donor centers in the same areas. The replication cohort included 5524 patients with SLE and 9859 healthy controls of European descent, initially enrolled for a study published in 2017.2 Genotyping data were collected from both cohorts using a 200K Immunochip single nucleotide polymorphism array. Cumulative GRSs were assigned to each study participant based on 57 SNPs with known associations to SLE. Risk allele counts of the 57 SNPs were calculated for each participant by summing the total number of risk alleles. Ordinal and logistic regression were used to assess GRS differences between patients and healthy controls.

Results indicated that SLE was more prevalent in the high GRS quartile compared with the low GRS quartile in both the discovery (odds ratio [OR], 12.32; 95% CI, 9.53-15.71; P =7.910-86) and replication (OR, 7.48; 95% CI, 6.73-8.32; P =2.210-304) cohorts. In the discovery cohort, compared with patients in the low GRS quartile, those in the high GRS quartile had a 6-year earlier mean disease onset (33 vs 39 years; P =4.310-5), higher prevalence of damage accrual (OR, 1.47; 95% CI, 1.06-2.04; P =2.010-2), and higher prevalence of any renal disorder (OR, 2.22; 95% CI, 1.50-3.27; P =5.910-5), end-stage renal disease (OR, 5.58; 95% CI, 1.50-20.79; P =1.010-2), and proliferative nephritis (OR, 2.42; 95% CI, 1.30-4.49; P =5.110-3).

Patients in the high GRS quartile vs the low GRS quartile of the discovery cohort were also more likely to have a positive antiphospholipid antibodies test (OR, 1.84; 95% CI, 1.16-2.9; P =9.410-3), with more than doubled odds of being triple positive (OR, 2.27; 95% CI, 1.02-5.09; P =4.610-2). In survival analyses conducted in the discovery cohort, compared with the low GRS quartile, the high GRS quartile displayed earlier onset of first organ damage (43 vs 51 years), first cardiovascular event (45 vs 51 years), nephritis (31 vs 39 years), and end-stage renal disease (43 vs 64 years). Decreased overall survival was also observed in the high-to-low quartile comparisons (hazard ratio, 1.83; 95% CI, 1.02-3.30; P =4.310-2).

These data support the prognostic capacity of GRS for SLE outcomes. The highest GRS quartile was strongly associated with poorer outcomes, including organ damage, cardiovascular events, renal dysfunction, and all-cause mortality. Our results indicate that genetic profiling may be useful for predicting outcomes in patients with SLE, the investigators wrote.

References

1. Reid S, Alexsson A, Frodlund M, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus [published online December 11, 2019]. Ann Rheum Dis. doi:10.1136/annrheumdis-2019-216227

2. Langefeld CD, Ainsworth HC, Vyse TJ. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017;8:16021.

Excerpt from:
High Genetic Risk Score Associated With Organ Damage, Renal Dysfunction, and All-Cause Mortality in SLE - Rheumatology Advisor

Read More...

Filling In The Gaps Of Asia’s Genetic Map – Asian Scientist Magazine

Wednesday, January 15th, 2020

AsianScientist (Jan. 14, 2019) An international team of scientists has sequenced the genomes of almost 2,000 Asians to find clues about Asian ancestry, health and disease. Their findings are published in Nature.

Despite forming over 40 per cent of the worlds population, Asian people have previously accounted for only six per cent of the worlds recorded genome sequences.

To raise the representation of Asian genomes in biomedical studies, Nanyang Technological University, Singaporetogether with Macrogen, South Korea; Genentech, US; and MedGenome, India/USlaunched the GenomeAsia 100K consortium in 2016. The consortium aims to understand the genome diversity of Asian ethnicities by sequencing 100,000 genomes of people living in Asia.

GenomeAsia 100K is a significant and far-reaching project that will affect the well-being and health of Asians worldwide, said NTU Professor Stephan C. Schuster, the consortiums scientific chairman and a co-leader of the study.

In the present study, the researchers analyzed the genomes of 1,739 people, which represents the widest coverage of genetic diversity in Asia to date. Genomic DNA was extracted from blood and saliva samples, then sequenced in the laboratories of the four consortium members. The digital sequencing data were subsequently sent to Singapore for processing and storage.

Zooming in on the frequencies of known genetic variants related to adverse drug response, the team reported that Warfarin, a common anticoagulant drug prescribed to treat cardiovascular diseases, has a higher frequency of appearance in individuals with North Asian ancestry, such as Japanese, Korean, Mongolian or Chinese.

Using this data, scientists can now screen populations to identify groups that are more likely to have a negative predisposition to a specific drug. Knowing a persons population group and their predisposition to drugs is extremely important if personalized medicine is to work, Schuster emphasized.

In addition, the researchers discovered that Asia has at least ten ancestral lineages, whereas northern Europe has a single ancestral lineage. Moving forward, the GenomeAsia 100K consortium will continue to collect and analyze up to 100,000 genomes from all of Asias geographic regions to fill in the gaps of the worlds genetic map and to account for Asias unexpected genetic diversity.The article can be found at: GenomeAsia100K Consortium (2019) The GenomeAsia 100K Project Enables Genetic Discoveries Across Asia.

Source: Nanyang Technological University; Photo: Shutterstock.Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

More here:
Filling In The Gaps Of Asia's Genetic Map - Asian Scientist Magazine

Read More...

The Chinese Scientist Who Made The First Genetically Engineered Babies Is Going To Prison – BuzzFeed News

Tuesday, December 31st, 2019

A Chinese court sentenced biomedical scientist He Jiankui and two accomplices to prison on Monday for illegal medical practice for genetically engineering three babies.

In November 2018, He announced the birth of the first two children, twin girls named Lulu and Nana, as well as the pregnancy of a second woman carrying a genetically engineered fetus. The news created a scientific firestorm, with human genetic engineering experiments widely viewed as dangerous and unethical by scientific organizations worldwide. The third baby has now been born, according to reporting from Chinas state news agency.

The genetic engineering team fabricated an ethics review of their experiment, according to the Nanshan District People's Court of Shenzhen City ruling. They used the faked permissions to recruit couples living with HIV in hopes of helping them to conceive children genetically engineered to receive a mutation giving them immunity to some forms of the disease.

He, formerly a biomedical scientist at the Southern University of Science and Technology in Shenzen, received a prison sentence of three years and a fine equivalent to $480,000. His associates, Zhang Renli and Qin Jinzhou, received jail terms of two years and 18 months with a two-year reprieve, according to the ruling, for practicing medicine without a license and violating Chinese regulations governing assisted reproduction.

The prison sentence and stiff financial penalty sends a message to other Chinese scientists that unsanctioned efforts at human germline editing will not be tolerated, University of Pennsylvania Perelman School of Medicine researcher Kiran Musunuru told BuzzFeed News, by email. I expect that it will have a deterrent effect, certainly in China and possibly elsewhere.

At an October conference, Musunuru had reported that a draft study submitted to a scientific journal about the twins by Hes team suggested that the genetic engineering attempt had badly misfired, targeting the wrong location for the mutation and potentially seeding other mutations throughout the DNA of the children.

Science academies worldwide formed an oversight commission in March, following widespread condemnation of the experiments.

The court ruling found the three sentenced scientists acted "in the pursuit of personal fame and gain" and have seriously "disrupted medical order, according to Chinese state media.

More:
The Chinese Scientist Who Made The First Genetically Engineered Babies Is Going To Prison - BuzzFeed News

Read More...

Our 10 most read stories of 2019: genetics, TV, ‘Barbie Death Camp’ and more – The Jewish News of Northern California

Tuesday, December 31st, 2019

It was quite a year for the Jews of the Bay Area. From TV shows to Barbie Death Camp to white supremacists to racial diversity in the Jewish community, here are the 10 stories our online readers clicked on the most in 2019.

It was a big year for Israeli TV in America. One show in particular, Shtisel, became an unlikely crossover hit among American viewers when the 2013-2016 series about the travails of a haredi family in Jerusalem hit Netflix late last year. As our TV reviewer Esther D. Kustanowitz wrote in January, there are some universal themes about family, community and change that kept mainstream audiences fascinated by the show:

In September, we brought you perhaps the strangest piece of news we covered this year: the curious case of Burning Mans Barbie Death Camp display. Heres how reporter Gabe Stutman described it: A sea of nude Barbies is seen moving toward three full-size kitchen ovens. Some are crucified on bright pink crosses. Other photos show toy soldiers with semi-automatic rifles marching the Barbies from the rear. A banner strapped to an RV proclaims the Barbie Death Camp the friendliest concentration camp at Burning Man. Another reads arbeit macht plastik frei, a reference to the message over the Auschwitz gate meaning work makes you free.

Some might say its the least Jewish story we wrote this year, but I beg to differ. My visit to the recently remodeled Church of Jesus Christ of Latter-day Saints Temple in Oakland was a personal highlight of the year. It was the first time it had been open to the public in over 50 years, and the visit did not disappoint. As I wrote at the time: I was there out of my love of religious architecture and because Id heard that [Mormon temples] include architectural references to the Mishkan (the portable sanctuary used by the Israelites as they wandered in the desert), as well as the ancient Temples that stood on Jerusalems Temple Mount.

No one article about him truly topped the list, but weve been covering the story since the 24-year-old Concord man was arrested in June and accused of plotting online to shoot Jews. Police found a weapons cache and Nazi literature in his home. He has been in and out of court and jail since then. Last month, a federal charge was added: In 2017, he falsified an application to join the Army by lying about his mental health history, according to the FBI. His bail has been revoked and he remains in custody as his case progresses.

This profile of iconoclastic billionaire Craig Newmark, founder of Craigslist, was the first in-depth interview he has given about his Jewish upbringing and values. More and more Im conscious of the notion of treating people like I want to be treated, and more and more Im conscious of the notion that I got lucky financially and I should share that in ways that mean something, he told our late colleague Rob Gloster in April.

The 2018 Portrait of Bay Area Jewish Life and Communities revealed that one-quarter of local Jewish households include at least one person of color. In our Jan. 25 editorial, we wrote: Its time we acknowledge not only the tendency to make Jews the other in broader society, but the equally pernicious tendency to other Jews of color right here within our own community. Our cover story is replete with stories from Jews of color being stared at or questioned when they show up in synagogue, and being passed over for leadership positions. But we also highlighted ways in which the situation is changing for the better.

Remember this years middling Netflix film The Red Sea Diving Resort, based on the secret Israeli plan to extract Ethiopian Jews through Sudan in the early 80s? Yeah, theres no reason you should. Much more interesting is the real-life story of one of the Israeli naval commandos who took part in the operation. Nir Merry lives in Mountain View today, and as he told editorial assistant Gabriel Greschler, during the operation he spent nights picking up Ethiopian Jews who had hiked for days, sometimes weeks, to reach the rendezvous point. He recalled avoiding armed Sudanese patrols on the coastline and ferrying the refugees to a disguised Israeli Navy ship in the Red Sea. We were tired but really excited, Merry said. I remember picking [up] an [Ethiopian] lady and you could hear little squeaks. And I realized it was a baby tucked in her dress close to her body.

Just last week, Adam Eilath, head of school at Ronald C. Wornick Jewish Day School in Foster City, registered his dismay at the Hanukkah-themed episode of the Disney series Elena of Avalor. In his opinion piece he wrote, As a Sephardic Jew raising two small daughters in an American Jewish community whose default is almost always Ashkenazi. I was excited that the episode would feature Princess Rebekah from a Latino (Ladino) Jewish kingdom. But, he continued, As usual, the only way that Sephardic culture gets represented in this episode is by incorporating Sephardic food.

This story was part of a three-part series on the rise of home genetic testing and the ease of doing genealogical research from the comfort of your home computer. One woman we spoke with grew up Catholic, but found out that she was 50% Asheknazi Jewish from a 23andMe home genetic test. But, as reporter Maya Mirsky asks, what does that really mean? The question itself is a new wrinkle in the age-old debate of just what it means to be Jewish, which has been given a kick in the pants from the commercialization of a field of science that says it can tell you something new: For a price, you can now choose from one of seven commercial genetic tests to find out just how Jewish you are.

In October we reported on a Nazi flag seen hanging inside a state parole office in Sacramento. How did it get there? And why was it hanging in a government building? The California Department of Corrections and Rehabilitation told us in an email that they have a zero tolerance policy for the display of objects that are derogatory in nature, but they pointed out that their officers deal with gang members and high-risk sex offenders, [so] we will come into contact with items that may be considered objectionable. However, the email continued, We take this issue seriously and have removed the item and are looking into the circumstances for why the flag was displayed in potential view of the public. No word yet on what they found out.

View post:
Our 10 most read stories of 2019: genetics, TV, 'Barbie Death Camp' and more - The Jewish News of Northern California

Read More...

Page 25«..1020..24252627..3040..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick